Advertisement
RVTY vs TMO
Which Stock Would AI Choose? Revvity (RVTY) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- Revvity (RVTY) has delivered stronger recent momentum with double-digit weekly gains and significant year-to-date outperformance compared to Thermo Fisher Scientific (TMO).
- Both companies operate in the life sciences and diagnostics sector, with TMO maintaining a substantially larger market capitalization and broader operational scale.
- RVTY has announced strategic moves such as the planned acquisition of Human Cell Design to expand its offerings in metabolic disease research.
- TMO recently completed the sale of its microbiology business and advanced acquisitions including Clario Holdings to strengthen clinical trial capabilities.
- Relative performance shows RVTY with higher volatility and faster recent price appreciation, while TMO exhibits more consistent stability and diversified revenue streams.
- Market sentiment favors RVTY in the short term due to conference presentations and backlog strength, whereas TMO benefits from established market leadership and steady order trends.
Introduction
Revvity (RVTY) and Thermo Fisher Scientific (TMO) represent two prominent players in the life sciences tools and diagnostics industry. Investors and traders often compare these stocks to evaluate relative positioning within healthcare innovation, particularly amid evolving demand for research instruments, reagents, and clinical solutions. This analysis examines their business models, recent stock behavior, and key contrasts to assist those assessing portfolio allocation or tactical trading opportunities in the sector. The comparison draws on observable market data and developments to highlight trade-offs in growth profiles and risk exposures.
RVTY Overview and Recent Performance
Revvity, Inc. provides health sciences solutions, including instruments, reagents, software, and detection technologies for life sciences and diagnostics markets. Formerly known as PerkinElmer, the company rebranded in 2023 to focus on translational multi-omics and biomarker applications. In recent market activity, RVTY shares have shown notable strength, including a five-day winning streak with cumulative gains exceeding 20% amid presentations at healthcare conferences and optimism around margin targets. Strategic developments, such as the planned acquisition of Human Cell Design for advanced cell models in metabolic research, have contributed to positive sentiment. The stock has outperformed broader indices on a year-to-date basis, supported by a record instrument backlog and adjusted guidance increases.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. delivers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products through four primary segments. Headquartered in Waltham, Massachusetts, like Revvity, TMO serves pharmaceutical, biotech, academic, and clinical customers globally. Recent performance reflects steady operations, with the company completing the $1.1 billion sale of its microbiology business to Astorg and advancing the integration of Clario Holdings for enhanced clinical trial data capabilities. Order trends have remained resilient, with management noting orders outpacing revenue in certain areas during investor events. The stock has posted more moderate year-to-date returns compared to smaller peers, consistent with its established scale and diversified end-market exposure.
Trending AI Robots
Tickeron operates a platform featuring hundreds of AI trading bots that execute strategies across thousands of tickers, encompassing varied styles, timeframes, performance metrics, and risk parameters. Only the most suitable bots for prevailing market conditions are featured in the curated Trending AI Robots section, providing users with access to data-driven options that adapt to trends in volatility, momentum, and sector rotation. Available bots demonstrate a range of historical win rates, drawdown profiles, and trade frequencies, allowing selection based on individual objectives. This resource supports informed exploration of automated trading approaches without replacing independent analysis.
Head-to-Head Comparison
Revvity (RVTY) operates with a narrower focus on life sciences and diagnostics workflows, while Thermo Fisher Scientific (TMO) maintains broader exposure across analytical instruments and biopharma services, resulting in greater revenue diversification for TMO. Growth drivers for RVTY include targeted acquisitions and instrument demand in pharma and biotech, whereas TMO benefits from scale in clinical trial support and laboratory products. Recent momentum has favored RVTY with sharper price advances and elevated volatility, contrasting TMO’s more measured trajectory. Risk factors for RVTY encompass higher valuation multiples and execution on smaller-scale deals; TMO faces integration challenges from larger transactions but benefits from stronger balance sheet metrics. Sector exposure overlaps significantly in healthcare innovation, yet TMO’s larger market capitalization correlates with lower relative beta in recent periods. Market sentiment reflects short-term enthusiasm for RVTY’s catalysts alongside TMO’s reputation for operational consistency.
Tickeron AI Verdict
Based on observable factors including trend consistency, backlog indicators, and relative positioning, Tickeron’s AI models would currently assign a higher probabilistic preference to Revvity (RVTY) for momentum-driven scenarios, while noting Thermo Fisher Scientific (TMO) for stability-oriented allocations. This assessment reflects recent price behavior and catalyst visibility rather than forward projections.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RVTY is a Hold and TMO is a Buy.
RVTY | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 30 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 15 Undervalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 72 | |
SMR RATING 1..100 | 87 | 60 | |
PRICE GROWTH RATING 1..100 | 9 | 20 | |
P/E GROWTH RATING 1..100 | 9 | 20 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (13) in the Medical Specialties industry is in the same range as RVTY (15). This means that TMO’s stock grew similarly to RVTY’s over the last 12 months.
TMO's Profit vs Risk Rating (72) in the Medical Specialties industry is in the same range as RVTY (100). This means that TMO’s stock grew similarly to RVTY’s over the last 12 months.
TMO's SMR Rating (60) in the Medical Specialties industry is in the same range as RVTY (87). This means that TMO’s stock grew similarly to RVTY’s over the last 12 months.
RVTY's Price Growth Rating (9) in the Medical Specialties industry is in the same range as TMO (20). This means that RVTY’s stock grew similarly to TMO’s over the last 12 months.
RVTY's P/E Growth Rating (9) in the Medical Specialties industry is in the same range as TMO (20). This means that RVTY’s stock grew similarly to TMO’s over the last 12 months.
| RVTY | TMO | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 78% | 3 days ago 55% |
| Stochastic ODDS (%) | 3 days ago 77% | 3 days ago 56% |
| Momentum ODDS (%) | 3 days ago 72% | 3 days ago 70% |
| MACD ODDS (%) | 3 days ago 72% | 3 days ago 63% |
| TrendWeek ODDS (%) | 3 days ago 67% | 3 days ago 62% |
| TrendMonth ODDS (%) | 3 days ago 64% | 3 days ago 62% |
| Advances ODDS (%) | 7 days ago 66% | 7 days ago 62% |
| Declines ODDS (%) | 14 days ago 67% | 16 days ago 62% |
| BollingerBands ODDS (%) | 3 days ago 82% | 3 days ago 56% |
| Aroon ODDS (%) | 3 days ago 55% | 3 days ago 59% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RVTY’s FA Score shows that 3 FA rating(s) are green while TMO’s FA Score has 3 green FA rating(s).
- RVTY’s FA Score: 3 green, 2 red.
- TMO’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RVTY’s TA Score shows that 4 TA indicator(s) are bullish while TMO’s TA Score has 5 bullish TA indicator(s).
- RVTY’s TA Score: 4 bullish, 4 bearish.
- TMO’s TA Score: 5 bullish, 4 bearish.
Price Growth
RVTY (@Medical Specialties) experienced а +11.75% price change this week, while TMO (@Medical Specialties) price change was +2.67% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +5.02%. For the same industry, the average monthly price growth was +3.27%, and the average quarterly price growth was +48.78%.
Reported Earning Dates
RVTY is expected to report earnings on Nov 02, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Medical Specialties (+5.02% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement